THE Therapeutic Goods
Administration has updated its
AusPAR listing to include information
on Nitisinone and Filgrastim.
Nitisinone is an oral capsule
approved for the treatment of
hereditary tyrosinaemia type 1 in
combination with dietary restriction
of tyrosine and phenylalanine.
Filgrastim comes in a pre-filled
syringe and is approved for seven
therapeutic uses including, the
reduction of the duration of
neutropenia and clinical sequelae
in patients undergoing induction
and consolidation chemotherapy
for acute myeloid leukaemia.
MEANWHILE the TGA has also
published a draft compositional
guideline for steviol glycosides,
which is available to to be viewed
via its website- www.tga.gov.au.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 11
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.